Retatrutide
What it is
Retatrutide (LY3437943) is a synthetic peptide that activates three receptors involved in energy balance: GIP, GLP-1 and glucagon. It has been studied in clinical trials and is supplied here as a research reagent in vials of 10 mg and 15 mg and as a 40 mg QuickPen.
Where it has been studied
- Multi-receptor incretin pharmacology
- Body weight and glycaemic models
- Hepatic fat studies
Selected literature
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 TrialJastreboff AM et al. · N Engl J Med, 2023 · PMID 37366315
- Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trialBajaj HS et al. · Lancet, 2026 · PMID 42250575
PubMed records selected for relevance to the compound. They describe published research, not outcomes or uses.
